The effect of menopausal hormone therapy on the risk of melanoma and keratinocyte skin cancer: A systematic review and meta-analysis of observational studies.
Basal cell carcinoma
Keratinocyte cancer
Melanoma
Menopausal hormone therapy
Skin cancer
Squamous cell carcinoma
Journal
Maturitas
ISSN: 1873-4111
Titre abrégé: Maturitas
Pays: Ireland
ID NLM: 7807333
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
23
03
2022
revised:
10
09
2022
accepted:
26
10
2022
pubmed:
14
11
2022
medline:
11
1
2023
entrez:
13
11
2022
Statut:
ppublish
Résumé
Whether menopausal hormone therapy (MHT) increases the risk of skin cancer is controversial. To systematically review and meta-analyze evidence regarding the association of MHT with the risk of melanoma and keratinocyte cancer (KC). A comprehensive literature search was conducted of the PubMed, Scopus and Cochrane databases, through to 30 October 2021. Skin neoplasms were divided into melanoma and KC. In the latter category, both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) were considered. The results are presented as hazard ratios (HR) with 95 % confidence intervals (CI). The I Twenty-seven studies were included in the qualitative and 23 in the quantitative analysis, with a total of 2,612,712 menopausal women (25,126 with skin cancer; 20,150 with melanoma). MHT was associated with an increased risk of melanoma (HR 1.11; 95 % CI 1.05-1.19; I The use of MHT by postmenopausal women was associated with an increased risk of melanoma and KC. This risk was higher for current MHT users and those treated for over 5 years.
Sections du résumé
BACKGROUND
BACKGROUND
Whether menopausal hormone therapy (MHT) increases the risk of skin cancer is controversial.
AIM
OBJECTIVE
To systematically review and meta-analyze evidence regarding the association of MHT with the risk of melanoma and keratinocyte cancer (KC).
MATERIAL AND METHODS
METHODS
A comprehensive literature search was conducted of the PubMed, Scopus and Cochrane databases, through to 30 October 2021. Skin neoplasms were divided into melanoma and KC. In the latter category, both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) were considered. The results are presented as hazard ratios (HR) with 95 % confidence intervals (CI). The I
RESULTS
RESULTS
Twenty-seven studies were included in the qualitative and 23 in the quantitative analysis, with a total of 2,612,712 menopausal women (25,126 with skin cancer; 20,150 with melanoma). MHT was associated with an increased risk of melanoma (HR 1.11; 95 % CI 1.05-1.19; I
CONCLUSION
CONCLUSIONS
The use of MHT by postmenopausal women was associated with an increased risk of melanoma and KC. This risk was higher for current MHT users and those treated for over 5 years.
Identifiants
pubmed: 36372010
pii: S0378-5122(22)00233-X
doi: 10.1016/j.maturitas.2022.10.010
pii:
doi:
Substances chimiques
Estrogens
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
20-28Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no competing interest.